Wuhan Heyi Biotechnology

Healthgen Biotech is a clinical-stage biopharmaceutical company based in Wuhan, China, specializing in the development and manufacture of plant-derived recombinant proteins. The company utilizes its proprietary OryzHiExp platform to express high-purity proteins in rice seeds, providing a safe, scalable, and animal-free alternative to human-plasma-derived products. Its lead candidate, OsrHSA (recombinant human serum albumin), is currently in Phase 3 clinical trials for treating hypoalbuminemia and liver cirrhosis, addressing a critical global shortage of albumin. Healthgen's pipeline also includes recombinant alpha-1 antitrypsin and lactoferrin, targeting inflammatory and infectious diseases. The company's molecular farming technology represents a significant innovation in biomanufacturing, offering high capacity and reduced risk of pathogen transmission.